The Potential Safe Antifibrotic Effect of Stem Cell Conditioned Medium and Nilotinib Combined Therapy by Selective Elimination of Rat Activated HSCs.
Animals
Apoptosis
/ drug effects
Cell Survival
/ drug effects
Cells, Cultured
Collagen
/ metabolism
Combined Modality Therapy
Culture Media, Conditioned
/ pharmacology
Cytochromes c
/ metabolism
DNA
/ metabolism
Hepatic Stellate Cells
/ drug effects
Inhibitory Concentration 50
Liver Cirrhosis
/ drug therapy
Male
Mesenchymal Stem Cells
/ chemistry
Models, Biological
Oxidative Stress
/ drug effects
Pyrimidines
/ pharmacology
Rats, Sprague-Dawley
Reactive Oxygen Species
/ metabolism
Tumor Suppressor Protein p53
/ metabolism
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
10
2020
revised:
13
02
2021
accepted:
19
03
2021
entrez:
15
4
2021
pubmed:
16
4
2021
medline:
27
5
2021
Statut:
epublish
Résumé
Hepatic fibrosis is a progressive disease with serious clinical complications that arise from abnormal propagation and activation of multiple inflammatory pathways. Nilotinib is an oral tyrosine kinase inhibitor with antifibrotic activity. Mesenchymal stem cells (MSCs) are blank cells and can differentiate into specific cell types. They have the potential to repair and regenerate cells. MSCs have a special paracrine fashion where they produce special exosomes, microvesicles, and cytokines like IL-6, transforming growth factor-beta (TGF-
Identifiants
pubmed: 33855079
doi: 10.1155/2021/6678913
pmc: PMC8021473
doi:
Substances chimiques
Culture Media, Conditioned
0
Pyrimidines
0
Reactive Oxygen Species
0
Tumor Suppressor Protein p53
0
Collagen
9007-34-5
Cytochromes c
9007-43-6
DNA
9007-49-2
nilotinib
F41401512X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6678913Informations de copyright
Copyright © 2021 Ahmed Nabil et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Hepatology. 2008 May;47(5):1634-43
pubmed: 18395843
World J Gastroenterol. 2015 Jan 21;21(3):742-58
pubmed: 25624709
Cell Transplant. 2007;16(7):717-28
pubmed: 18019361
J Hepatol. 2015 Mar;62(3):634-41
pubmed: 25450712
Eur J Pharmacol. 2008 Dec 3;599(1-3):44-53
pubmed: 18938156
Blood. 2008 Jan 1;111(1):430-8
pubmed: 17909081
Hepatology. 2013 Jan;57(1):311-9
pubmed: 22829291
Trans Am Clin Climatol Assoc. 2009;120:361-8
pubmed: 19768189
Liver Int. 2008 Apr;28(4):546-57
pubmed: 18339080
Life Sci. 2011 Dec 19;89(25-26):975-81
pubmed: 22056375
Stem Cells Int. 2020 Feb 3;2020:6574010
pubmed: 32089708
Am J Transl Res. 2019 Mar 15;11(3):1230-1240
pubmed: 30972158
Physiol Rev. 2008 Jan;88(1):125-72
pubmed: 18195085
Oncogene. 2002 Feb 7;21(7):1108-16
pubmed: 11850828
J Cell Mol Med. 2019 Mar;23(3):1657-1670
pubmed: 30635966
Clin Exp Pharmacol Physiol. 2014 Oct;41(10):788-97
pubmed: 25115651
Eur J Pharmacol. 2011 Nov 30;670(2-3):593-600
pubmed: 21925495
Front Biosci. 2003 Jan 01;8:d69-77
pubmed: 12456323
Methods Mol Med. 2005;117:99-113
pubmed: 16118448
Transplant Proc. 2012 May;44(4):1110-2
pubmed: 22564638
ACS Chem Biol. 2014 Mar 21;9(3):777-84
pubmed: 24397822
Gut. 2001 Apr;48(4):548-57
pubmed: 11247901
Arch Neurol. 2010 Oct;67(10):1187-94
pubmed: 20937945
Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):305-17
pubmed: 21497747
Anal Biochem. 1980 Mar 1;102(2):344-52
pubmed: 6158890
Oxid Med Cell Longev. 2020 May 28;2020:1362104
pubmed: 32566073
FASEB J. 2008 Jul;22(7):2214-22
pubmed: 18326784
Oncol Rep. 2019 Mar;41(3):1837-1850
pubmed: 30569155
PLoS One. 2012;7(10):e47559
pubmed: 23133515
J Hepatol. 2011 Sep;55(3):612-625
pubmed: 21251937